Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Palette Life Sciences Addresses Education and Training Needs of Pediatric Urologists through Expansive Global Digital Education Program


SANTA BARBARA, Calif. and STOCKHOLM, Jan. 19, 2021 /PRNewswire-PRWeb/ -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, continues to develop new resources and expand access to online training and education to meet the needs of caregivers, pediatric urologists and the global pediatric urology community who treat serious conditions such as vesicoureteral reflux (VUR). Providing digital access to resources is more important now than ever, given the current climate.

With COVID-19 impacting in-person training and education, Palette has focused on expanding the reach of digital educational content to the global pediatric urology community and to the caregivers and parents of children with VUR. With the recent launch of two new websites for Latin America and Brazil in Spanish and Portuguese, Palette has now launched a total of nine resource-rich localized websites in just the past five months, including the United States, United Kingdom, Australia, France, Germany, Italy and Spain.

The goal of this expansive digital education initiative is to elevate the standard of care for VUR patients globally by providing the healthcare community with valuable information, training, education and resources to learn more about the causes, risk factors, symptoms and treatment options, such as Deflux®. The websites offer local-language resources for healthcare providers and access to the global Deflux Learning Center, a leading education platform that features clinical articles, educational videos, webinars, brochures, downloadable tools and The PedSpace podcast series, created for and presented by pediatric urology healthcare professionals. In addition, Palette provides online resources for parents and caregivers, including information about VUR and how to find a specialist and receive diagnosis and treatment earlier in the process.

"2020 was an unprecedented year filled with unforeseen challenges, especially for the global healthcare community. Palette addressed these challenges rapidly by shifting our focus to find new ways to support the global pediatric urology ecosystem," said Richard Low, Head of Marketing at Palette Life Sciences. "While VUR education continues to be a main area of focus, the way we deliver it has changed. In-person Deflux injection trainings have become webinars, and The PedSpace podcast was developed as an additional educational resource for healthcare providers to share knowledge and perspectives. We developed Katie's Story to provide parents and caregivers with a resource that gives them more insight into the VUR journey and empowers them to seek out a pediatric urologist. As we enter a new year, we remain committed to continued innovation and expanding our delivery of educational resources to the global healthcare community."

About Deflux
Deflux is a minimally invasive, day procedure treatment that has been proven safe and effective in children with vesicoureteral reflux (VUR) grade 2-4 in the United States, and in all grades worldwide. VUR is a serious pediatric urinary condition in which urine backflows from the bladder through one or both ureters toward the kidneys, due to an abnormality at the junction of the ureter and the bladder. Deflux is an injectable gel bulking agent made from two tissue-friendly polysaccharides; Non-Animal Stabilized Hyaluronic Acid (NASHA®) and dextranomer (Dx) microspheres. The product is administered via injection in the ureteral tunnel to prevent urine reflux. For more information, visit http://www.deflux.com.

About Palette Life Sciences
Palette Life Sciences is a fully integrated life sciences company. Palette Life Sciences' products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company's portfolio of available products includes Deflux®, Barrigel®, Solesta®, and Lidbreetm. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, Dallas, Texas, and Sydney, Australia. Learn more at http://www.palettelifesciences.com.

Deflux®, and Palette Life Sciencestm and are registered trademarks. All rights reserved.

Media Contact

Danielle Hazarian, Palette Life Sciences, +1 (805) 458-0943, [email protected]

 

SOURCE Palette Life Sciences


These press releases may also interest you

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...

at 06:50
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZtm (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis...

at 06:08
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...



News published on and distributed by: